CED Life Science Conference 2018 - Lightning Round; Innovation Room
(website in development)
Sub-sector: Biotech and Pharmaceutical
Year Founded: 2015
PhosphoGam is a pre-clinical cell therapy company focused on using gamma/delta T cells (γδ-T cells) obtained from healthy (allogeneic) donors to treat a variety of cancers. In contrast to conventional T cells, γδ-T cells can rapidly recognize and kill a wide variety of tumor cells, regardless of tissue of origin. This feature makes γδ-T cells ideal for use as an “off-the-shelf” cell therapy. Although γδ-T cells are extremely rare, PhosphoGam has developed the means to generate (manufacture) large numbers of γδ-T cells obtained from healthy donors for subsequent treatment for virtually any patient with any type of cancer. Moreover, in contrast to CAR-T cells (which can recognize only one pre-selected target), the “universal killer” γδ-T cells produced by PhosphoGam can be generated simply and reliably — without need of complex and costly genetic manipulations.
Dr. Richard Lopez - CEO
Tim Gallagher - CBO
KEY MILESTONES TO DATE
- Technical operations have commenced at BioLabs NC. Our next milestone is to produce sufficient data to win pharma and investor attention, in 1Q2018.
Duke Office of Licensing and Ventures (OLV); LaunchBio
Learn more about the CED Life Science Conference.